Obesity is a complex condition with many comorbidities. At Cleveland Clinic, bariatric surgeons and endocrinologists collaborate to optimize weight loss outcomes, as well as pre- and postoperative nutrition. In this article, Drs. Ali Aminian and Sangeeta Kashyap discuss their collaboration.
Patients can expect to lose additional weight on canagliflozin after weight loss plateau following metabolic surgery, according to a recently published randomized clinical trial. Endocrinologist Sangeeta Kashyap, MD, explains.
Supplementing with vitamin D3 has no significant clinical impact on diabetes prevention, according to a randomized clinical trial published in the New England Journal of Medicine.
Subanalysis of STAMPEDE trial data suggests the percentage of weight loss in the first year following surgery may be more important to diabetes management than weight fluctuations in the first five years.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Study shows that formerly obese men with T2D can enjoy the benefits of higher testosterone levels for at least five years following bariatric surgery.
Ancillary study to STAMPEDE study measures the five-year outcomes of bariatric surgery versus guideline-recommended intensive medical therapy on bone turnover in obese patients.
A Cleveland Clinic study reveals a mechanism that rapidly destroys high-density lipoprotein (HDL) in people with Type 2 diabetes, negating cardiovascular protections.
Cleveland Clinic researchers are heading the first long-term study to evaluate the effectiveness of bariatric surgery compared with medical therapy for treating Type 2 diabetes.
Weight loss maintenance following very-low-calorie meal plans has been poorly studied until recently. The Cleveland Clinic Department of Endocrinology looked at weight loss efficacy and predictors of long-term weight loss on a ketogenic diet.
Cleveland Clinic study highlights the increased cancer risk in diabetics while providing insights into oral insulin sensitizers that decrease malignancy risk in diabetic women.